IKZF1 and plasma cell myeloma: Nonetheless, bortezomib could potentiate the anti-myeloma effect of lenalidomide (16, 59), suggesting that bortezomib may regulate the CRBN–lenalidomide–IKZF1/3 signaling pathway.